G
Gerard Groenewegen
Publications - 2
Citations - 214
Gerard Groenewegen is an academic researcher. The author has contributed to research in topics: Pembrolizumab & Population. The author has an hindex of 2, co-authored 2 publications receiving 23 citations.
Papers
More filters
Journal ArticleDOI
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial
Alexander M.M. Eggermont,Christian U. Blank,Mario Mandalà,Georgina V. Long,Victoria Atkinson,Stéphane Dalle,Andrew Haydon,Andrey Meshcheryakov,Adnan Khattak,Matteo S. Carlino,Shahneen Sandhu,James Larkin,Susana Puig,Paolo A. Ascierto,Piotr Rutkowski,Dirk Schadendorf,Rutger H. T. Koornstra,Leonel Hernandez-Aya,Anna Maria Di Giacomo,Alfonsus J M van den Eertwegh,Jean-Jacques Grob,Ralf Gutzmer,Rahima Jamal,Paul Lorigan,Alexander C.J. van Akkooi,Clemens Krepler,Nageatte Ibrahim,Sandrine Marreaud,Michal Kicinski,Stefan Suciu,Caroline Robert,Alex Menzies,Thierry Lesimple,Michele Maio,Gerald P. Linette,Michael C. Brown,Peter Hersey,Inge Marie Svane,Laurent Mortier,Jacob Schachter,Catherine Barrow,Ragini R. Kudchadkar,Xinni Song,Caroline Dutriaux,Pietro Quaglino,Friedegund Meier,Paola Queirolo,Daniil Stroyakovskiy,Lars Bastholt,Bernard Guillot,Claus Garbe,Pablo Luis Ortiz Romero,Florent Grange,Peter Mohr,Alain Algazi,Oliver Bechter,Micaela Hernberg,Jean-Philippe Arnault,Philippe Saiag,Carmen Loquai,Frank Meiss,Jan-Christoph Simon,Gil Bar-Sela,Vanna Chiarion Sileni,Bernard Fitzharris,Mike McCrystal,Phillip Parente,Jean-Francois Baurain,Patrick Combemale,Céleste Lebbé,Axel Hauschild,Naoya Yamazaki,Reinhard Dummer,Mohammed M. Milhem,Marcin Dzienis,John Walker,Lionel Geoffrois,Marie-Thérèse Leccia,Lutz Kretschmer,Daniel Hendler,Michal Lotem,Andrzej Mackiewicz,Lidija Sekulovic,Elaine Dunwoodie,Christoph Hoeller,Laurent Machet,Jessica C. Hassel,Geke A. P. Hospers,Maria-Jose Passos,Max Levin,Martin Fehr,Philippa Corrie,Ashita Waterston,Sigrun Hallmeyer,Henrik Schmidt,Vincent Descamps,Jean-Philippe Lacour,Carola Berking,Felix Kiecker,Pier Francesco Ferrucci,Kenji Yokota,Maureen J.B. Aarts,Michael B. Jameson,Anna Katharina Winge-Main,Paula Ferreira,Kevin B. Kim,Catriona M. McNeil,Reiner Hofmann-Wellenhof,Joseph Kerger,François Aubin,Jochen Utikal,Virginia Ferraresi,Takashi Inozume,Yoshio Kiyohara,Gerard Groenewegen,Helena Kapiteijn,Suzana Matkovic,Wolf-Henning Boehncke,Richard Casasola,Timothy Crook,Ernest Marshall,Tanja Skytta,Marie-Francoise Avril,Thomas Jouary,Rüdiger Hein,Patrick Terheyden,Jun Aoi,Tatsuya Takenouchi,Oddbjorn Straume,César Martins,Guzel Mukhametshina,Paul C. Nathan +131 more
TL;DR: In this paper, the authors compared pembrolizumab versus placebo in patients with resected high-risk stage III melanoma, and showed that penglizumaab adjuvant therapy provided a significant and clinically meaningful improvement in distant metastasis-free survival at a 3·5-year median followup.
Journal ArticleDOI
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial
Andrew Bottomley,Corneel Coens,Justyna Mierzynska,Christian U. Blank,Mario Mandalà,Georgina V. Long,Victoria Atkinson,Stéphane Dalle,Andrew Haydon,Andrey Meshcheryakov,Adnan Khattak,Matteo S. Carlino,Shahneen Sandhu,Susana Puig,Paolo A. Ascierto,James Larkin,Paul Lorigan,Piotr Rutkowski,Dirk Schadendorf,Rutger H. T. Koornstra,Leonel Hernandez-Aya,Anna Maria Di Giacomo,Alfonsus J M van den Eertwegh,Jean-Jacques Grob,Ralf Gutzmer,Rahima Jamal,Alexander C.J. van Akkooi,Clemens Krepler,Nageatte Ibrahim,Sandrine Marreaud,Michal Kicinski,Stefan Suciu,Caroline Robert,Alexander M.M. Eggermont,Thierry Lesimple,Michele Maio,Gerald P. Linette,Laurent Mortier,Inge Marie Svane,Jacob Schachter,Michael C. Brown,Peter Hersey,Catherine Barrow,Ragini R. Kudchadkar,Caroline Dutriaux,Xinni Song,Pietro Quaglino,Paola Queirolo,Friedegund Meier,Daniil Stroyakovskiy,Bernard Guillot,Pablo Luis Ortiz Romero,Lars Bastholt,Claus Garbe,Florent Grange,Peter Mohr,Alain Algazi,Oliver Bechter,Micaela Hernberg,Carmen Loquai,Frank Meiss,Vanna Chiarion Sileni,Gil Bar-Sela,Bernard Fitzharris,Philippe Saiag,Jean-Philippe Arnault,Jan-Christoph Simon,Rosalie Stephens,Jean-Francois Baurain,Céleste Lebbé,Patrick Combemale,Reinhard Dummer,Axel Hauschild,Phillip Parente,Naoya Yamazaki,Mohammed M. Milhem,Marie-Thérèse Leccia,Lionel Geoffrois,Lutz Kretschmer,Elaine Dunwoodie,John Walker,Michal Lotem,Daniel Hendler,Andrzej Mackiewicz,Lidija Sekulovic,Marcin Dzienis,Geke A. P. Hospers,Marco Siano,Jessica C. Hassel,Philippa Corrie,Maria-Jose Passos,Max Levin,Christoph Hoeller,Laurent Machet,Sigrun Hallmeyer,Ashita Waterston,Vincent Descamps,Felix Kiecker,Maureen J.B. Aarts,Henrik Schmidt,Ana Raimundo,Marta Nyakas,Jean-Philippe Lacour,Carola Berking,Pier Francesco Ferrucci,Michael B. Jameson,Kevin B. Kim,Kenji Yokota,Joseph Kerger,François Aubin,Gerard Groenewegen,Helena Kapiteijn,Wolf-Henning Boehncke,Jochen Utikal,Richard Casasola,Ernest Marshall,Virginia Ferraresi,Erika Richtig,Suzana Matkovic,Takashi Inozume,Timothy Crook,Catriona M. McNeil,Yoshio Kiyohara,Marie-Francoise Avril,Rüdiger Hein,Patrick Terheyden,Paul C. Nathan,Jun Aoi,Tanja Skytta,Thomas Jouary,Tatsuya Takenouchi,Oddbjorn Straume,César Martins,Guzel Mukhametshina +133 more
TL;DR: The European Organisation for Research and Treatment of Cancer (EORTC) 1325-MG/KEYNOTE-054 trial in patients with resected, high-risk stage III melanoma demonstrated improved recurrence-free survival with adjuvant pembrolizumab compared with placebo (hazard ratio 0·57 [98·4% CI 0·43-0·74]; p<0·0001) as mentioned in this paper.